Loading
Enovis Corp Stock: price and insider trades · United States
2 insiders bought €387k of shares over the last 90 days, the latest by Engert Oliver, filed 08 Sept 2026.
Enovis Corp: what insiders have been doing
Every trade that managers of Enovis Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 21 October 2026, 51 filings were filed, from 18 insiders.
On the market, 3 insiders bought (14 purchases totalling €602k) while 1 insider sold (1 sale totalling €16k). On balance, insiders were net buyers of €586k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The largest single trade was a purchase of €215k by McDonald Damien, published on 4 September 2026, equal to 0.023% of the market capitalisation. On the buying side, the filings list 1 finance chief, 1 senior executive and 1 chief executive among the declarants.
With 51 filings in twelve months, the company is more active than the median of 22 filings across the 5,454 companies we follow on the same exchange. Since 2016, the database holds 21 purchases and 111 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 2.25 bn USD and net income of -1.18 bn USD.
The data flag 4 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (8 September 2026) now reads 43 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
555
Thresholds
n/a
Buy Volume
€6M
21 ops. · all time
Sell Volume
€16M
111 ops. · all time
Who traded when
BuySaleOliver Engert12 buys
Damien McDonald2 buys
Daniel A. Pryor1 buy1 sale
Bradley J. Tandy1 buy
John Kleckner1 buy
Phillip Benjamin (ben) Berry1 buy
Since the insiders bought
- +8.6%Entry US$19.03 · Close 20 Oct 2026 US$20.66
- +3.4%Entry US$19.98 · Close 20 Oct 2026 US$20.66
- -13.2%Entry US$29.36 · Close at T+90 US$25.47
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Enovis Corp Strong Buy (bullish), based on 12 analysts. Average price target: US$36.08.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,980 of 26,279 companies
27.8
score / 100
Value26
Quality30
FCF yld1.7%
Earn yld-103%
EV/EBITDA·
ROE-54%
Gross mgn60%
Net mgn-53%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$19.87
Analyst consensus
12 analystsStrong buy
US$24.00Target US$36.08(+82%)US$47.00
Income statement
RevenueUS$2.2B
Gross profitUS$1.3B60% margin
EBITDA-US$830.2M-37% margin
Net income-US$1.2B-48.0% margin
Valuation
PER (forward)5.6x
P/Book0.8x
Beta1.48
Balance sheet & cash
Market capUS$1.1B
Total debtUS$1.4B
Free Cash FlowUS$19.9M
Debt / Equity93%
Profitability & ownership
ROE-54.1%
ROA1.2%
% insiders1.6%
% institutions120.3%
Last declaration on 1 October 2026
Declarations555 total
958 shares0Common stock, par value $0.001SEC:0001193125-26-411063:0
2,660 shares@ US$18.800.0046% mcap25.0% of flowCommon stock, par value $0.001SEC:0001193125-26-385615:0
Canonical exit: 3 Dec 2026 (T+90)
13,035 shares@ US$19.150.023% mcap43.4% of flowCommon stock, par value $0.001SEC:0001193125-26-384027:0
Canonical exit: 3 Dec 2026 (T+90)
5,140 shares@ US$19.460.0093% mcap50.0% of flowCommon stock, par value $0.001SEC:0001193125-26-384028:1
Canonical exit: 2 Dec 2026 (T+90)
2,458 shares@ US$20.320.0047% mcap25.0% of flowCommon stock, par value $0.001SEC:0001193125-26-384028:0
Canonical exit: 1 Dec 2026 (T+90)
1,000 shares@ US$20.925.6% of flowCommon stock, par value $0.001SEC:0001193125-26-273151:0
Canonical exit: 13 Sept 2026 (T+90)
1,000 shares@ US$21.755.8% of flowCommon stock, par value $0.001SEC:0001193125-26-271546:1
Canonical exit: 9 Sept 2026 (T+90)
200 shares@ US$20.991.1% of flowCommon stock, par value $0.001SEC:0001193125-26-271546:0
Canonical exit: 9 Sept 2026 (T+90)
1,000 shares@ US$23.006.2% of flowCommon stock, par value $0.001SEC:0001193125-26-268213:0
Canonical exit: 8 Sept 2026 (T+90)
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235176:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235169:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235170:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235171:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235172:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235173:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235174:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235175:0
9,346 shares0Common stock, par value $0.001SEC:0001193125-26-235177:0
7,774 shares@ US$25.990.012% mcap31.3% of flowCommon stock, par value $0.001SEC:0001193125-26-224738:0
12,634 shares@ US$25.990.020% mcap56.6% of flowCommon stock, par value $0.001SEC:0001193125-26-224739:0
770 shares0Common stock, par value $0.001SEC:0001193125-26-140946:0
1,000 shares@ US$23.7423.1% of flowCommon stock, par value $0.001SEC:0001193125-26-108925:0
Canonical exit: 11 Jun 2026 (T+90)
1,000 shares@ US$23.9323.1% of flowCommon stock, par value $0.001SEC:0001193125-26-104643:0
Canonical exit: 8 Jun 2026 (T+90)
2,376 shares@ US$24.5165.9% of flowCommon stock, par value $0.001SEC:0001193125-26-100845:0
1,980 shares@ US$24.5151.8% of flowCommon stock, par value $0.001SEC:0001193125-26-100843:0
25 of 555 declarations
About Enovis Corp
Enovis Corp. (NYSE: ENOV) is a United States-based medical technology company listed on the NYSE/NASDAQ market. Headquartered in Dallas, Texas, Enovis positions itself as an innovation-driven orthopedic and medical technology growth company focused on improving clinical outcomes, functional recovery, and the efficiency of care pathways. The company’s operating model is organized around two main segments: Global Reconstructive, which includes orthopedic reconstruction technologies and implants, and Prevention & Recovery, which covers bracing, supports, rehabilitation products, and therapies designed to aid recovery and mobility. ([enovis.com](https://enovis.com/investors/press-releases/enovis-announces-fourth-quarter-and-full-year-2025-results?utm_source=openai))
Enovis’ corporate history reflects a deliberate portfolio shift toward higher-value orthopedic and musculoskeletal markets. A key milestone was the acquisition of LimaCorporate, which expanded the company’s reconstructive orthopedic footprint and strengthened its international scale, particularly in Europe. Management has repeatedly emphasized integration execution, commercial momentum, and operational discipline as the company absorbs that acquisition and pushes its strategy forward. ([ir.enovis.com](https://ir.enovis.com/node/18726/pdf?utm_source=openai))
Read moreShow less
From a product standpoint, Enovis serves surgeons, hospitals, ambulatory surgery centers, and patients through a broad portfolio that spans implants, surgical instruments, enabling technologies, orthotics, braces, and bone growth stimulation devices. In 2025, the company launched Manafuse, a bone growth stimulator using LIPUS technology, and continued to highlight innovation across surgery-assist technologies, patient-centered rehabilitation solutions, and digital healthcare capabilities. ([enovis.com](https://enovis.com/investors/press-releases/enovis-launches-manafuser-bone-growth-stimulator-lipus-technology?utm_source=openai))
Competitively, Enovis occupies a specialized position in a global orthopedic market dominated by larger medtech peers. Its differentiation comes from clinically oriented innovation, a portfolio that spans the treatment continuum from surgery to recovery, and a strategy that combines organic product development with targeted acquisitions. Rather than competing purely on scale, Enovis emphasizes solution depth, clinical differentiation, and workflow improvement for providers. The company also states that it operates with an extensive product and service base across global markets, with a meaningful presence in the United States and internationally. ([enovis.com](https://enovis.com/corporate-info/about-us?utm_source=openai))
Recent developments underscore a company that is still in transition but commercially active. Through late 2025 and into early 2026, Enovis announced new product launches, digital healthcare recognition, leadership changes, and ongoing progress on the Lima integration. Its 2025 results showed sales growth, but also large non-cash goodwill impairment charges, which highlight both the scale of the business transformation and the accounting volatility that can accompany acquisitions and market repricing. For investors, Enovis represents a U.S.-listed healthcare growth story with exposure to orthopedic recovery, innovation-led product cycles, and execution risk tied to integration and margin delivery. ([enovis.com](https://enovis.com/investors/press-releases/enovis-announces-fourth-quarter-and-full-year-2025-results?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
